cro.directory
← Compare landing

Cardiomedex vs Cyagen Biosciences

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/cardiomedex/cyagen

CategoryCardiomedexCyagen Biosciences
Listed sitecrocro
SummaryCardiomedex is a preclinical CRO specialized in cardiovascular disease models, offering in vivo efficacy studies, ex vivo functional exploration, and in vitro assays for drug candidates targeting heart failure, myocardial infarction, hypertension, and cardiometabolic complications.Cyagen provides genetically engineered animal models, custom cell lines, and viral packaging services for preclinical drug discovery, with specialized platforms including HUGO-GT™ and HUGO-Ab™ for humanized target validation and antibody screening.
Services
  • Cardiovascular & Metabolic Specialty Services
  • In Vivo Efficacy Models
  • Preclinical In Vivo Studies
  • In Vitro Pharmacology
  • Preclinical In Vitro Studies
  • Translational Research
  • Specialized & Large-Animal Models
  • In Vivo Efficacy Models
  • Preclinical In Vivo Studies
  • In Vitro Pharmacology
  • Preclinical In Vitro Studies
  • Translational Research
  • Immunology & Inflammation Services
  • Virology Services
Modalities
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
Indications
  • Cardiovascular
  • Metabolic
  • Oncology
  • Immunology
  • Neurology
  • Metabolic
  • Cardiovascular
  • Infectious Disease
  • Ophthalmology
Locations
  • Headquarters, Toulouse, France
  • Headquarters, Santa Clara, California, United States
CertificationsData not yet provided.
  • AAALAC International · Identifier: AAALAC-accredited facilities
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.